Top Story Today
Tempus Bets $1.5 Billion It Can Own the Entire Cancer Data Stack
Tempus AI agreed to acquire Personalis for $1.5 billion in stock, grabbing a blood test that detects leftover cancer cells at one part per million. The prize is Personalis's MRD (minimal residual disease) testing platform, which addresses a $20 billion market that's less than 10% penetrated. Wall Street was skeptical: both stocks fell 9%. Tempus isn't profitable yet, and this is its fourth major acquisition in two years. But the play is clear: build a single platform that handles tumor profiling, cancer monitoring, digital pathology, and AI-driven treatment recommendations, then let the data flywheel spin.
Why it matters: This deal signals that standalone cancer testing companies may be going extinct, replaced by vertically integrated platforms that combine diagnostics, AI, and data into one ecosystem. Whoever controls the data layer underneath oncology could control the treatment decisions that follow.
Read more →GLP-1 Wars
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads
Novo Nordisk filed a federal lawsuit alleging Lilly's Zepbound ads cherry-pick outdated trial data, comparing its max dose against Wegovy's older, lower dose while ignoring a newer 7.2 mg version that nearly closes the weight-loss gap. Novo wants a permanent injunction, corrective ads, and Lilly's profits from the campaigns. With both companies controlling a $100 billion-plus obesity market, this fight could reshape how GLP-1 drugs are marketed to millions.
Read more →Samsung Biologics Drops $1.8B on a Swiss Peptide Maker
One of the world's largest biologics contract manufacturers is buying PolyPeptide Group for $1.8 billion in cash, the biggest pharma M&A in South Korean history. The reason: GLP-1 drugs need specialized peptide manufacturing, and global capacity can't keep up with demand. PolyPeptide operates six sites across five countries.
Read more →Ozempic Just Lost Its Monopoly in a G7 Country
Aspen Pharmacare won Health Canada approval for generic semaglutide, joining Dr. Reddy's and Apotex in a growing field of Ozempic copycats. The opening came from an embarrassing slip: Novo Nordisk forgot to pay a Canadian patent maintenance fee. U.S. patents hold until 2032, but by late 2026, generics will be available in countries representing over 40% of the world's population.
Read more →Two Minutes to Decide If You Need Wegovy
Former LifeMD employees allege clinicians had roughly two minutes per patient to prescribe GLP-1 drugs, reviewing up to 25 cases per hour from online forms alone. LifeMD is one of Novo Nordisk's handpicked telehealth partners for its direct-to-consumer Wegovy distribution network. The FDA has already issued 30 warning letters to telehealth companies over GLP-1 marketing practices.
Read more →Clinical and Regulatory Wins
The Eye Disease Nobody Could Treat Just Met Its Match
Belite Bio's tinlarebant became the first drug ever to show clinical efficacy in Stargardt disease, reducing retinal lesion growth by 35.7% in a Phase 3 trial. The inherited condition, which typically robs teenagers of central vision, has had zero approved treatments for over 50 years. Belite is targeting an FDA submission in Q2 2026.
Read more →Dyne's Duchenne Drug Gets FDA Priority Review
The FDA accepted Dyne Therapeutics' application for z-rostudirsen with a January 2027 decision date. The drug produces roughly 10 times more dystrophin than the current approved exon 51 therapy, and all six prespecified functional endpoints improved at six months. For the 13% of Duchenne patients eligible for exon 51 skipping, the treatment landscape is shifting fast.
Read more →GSK Lands First Survival Win for a B7-H3 Cancer Drug
GSK's partner Hansoh delivered the first-ever Phase 3 overall survival win for a B7-H3-targeting antibody-drug conjugate, beating topotecan in small-cell lung cancer. B7-H3 shows up across a huge range of tumors while sparing healthy tissue, making it one of oncology's most coveted targets. Daiichi Sankyo, Roche, and others are racing close behind.
Read more →Big Pharma and Industry Watch
Novartis Lost Half Its Best-Seller. Wall Street Shrugged.
Entresto sales cratered 50% year-over-year as generics flooded in, yet Novartis posted resilient earnings. The secret: aggressive cost discipline and surging cancer drugs like Kisqali (up 43%) and Scemblix (up 79% at constant currencies). The company is also quietly building a kidney disease fortress with three drugs targeting IgA nephropathy through different mechanisms.
Read more →Abbott's Hackers Claim 30 Million Records. Abbott Says Everything's Fine.
Abbott acknowledged two cyberattacks in July, with hackers claiming over 30 million rows of personal data including Social Security numbers and doctor-patient notes. Abbott has not confirmed the scope of any data theft and has disputed the characterization of the data as sensitive. The company posted a strong $12.6 billion quarter and says operations are unaffected. Wall Street barely flinched, but the healthcare sector's cyberattack track record suggests the full picture may take months to emerge.
Read more →The Biotech CMO Who Didn't Exist
A most-wanted fugitive who vanished 20 years ago during a sexual assault trial was discovered working as chief medical officer of NASDAQ-listed Immix Biopharma under a fake identity. His fabricated resume claimed prestigious credentials and multiple approved drugs. Immix shares dropped 14%. The case exposes alarming gaps in how the biotech industry vets its leaders.
Read more →